Paolo Bidoli
Azienda Ospedaliera San Gerardo(IT)University of Milano-Bicocca(IT)
Publications by Year
Research Areas
Lung Cancer Treatments and Mutations, Lung Cancer Research Studies, Cancer Immunotherapy and Biomarkers, Colorectal Cancer Treatments and Studies, Cancer Treatment and Pharmacology
Most-Cited Works
- → Ramucirumab plus docetaxel versus placebo plus docetaxel for second-line treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy (REVEL): a multicentre, double-blind, randomised phase 3 trial(2014)1,290 cited
- → PARAMOUNT: Final Overall Survival Results of the Phase III Study of Maintenance Pemetrexed Versus Placebo Immediately After Induction Treatment With Pemetrexed Plus Cisplatin for Advanced Nonsquamous Non–Small-Cell Lung Cancer(2013)630 cited
- → Maintenance therapy with pemetrexed plus best supportive care versus placebo plus best supportive care after induction therapy with pemetrexed plus cisplatin for advanced non-squamous non-small-cell lung cancer (PARAMOUNT): a double-blind, phase 3, randomised controlled trial(2012)608 cited
- → Durvalumab as third-line or later treatment for advanced non-small-cell lung cancer (ATLANTIC): an open-label, single-arm, phase 2 study(2018)570 cited
- → Phase II Study of Pemetrexed Plus Carboplatin in Malignant Pleural Mesothelioma(2006)293 cited